KLWA
BIVV

Kelly Lawrence W & Associates’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Kelly Lawrence W & Associates’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4
Closed – – 220
2017
Q1 		$0 Buy
+4
New +$197 ﹤0.01% 234

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Kelly Lawrence W & Associates's BIVV Position: Q2 2017 in Review

Kelly Lawrence W & Associates sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 4 shares.

Kelly Lawrence W & Associates first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

  • Kelly Lawrence W & Associates reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Kelly Lawrence W & Associates sold 4 Bioverativ Inc. Common Stock shares in Q2 2017.
  • Kelly Lawrence W & Associates first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Kelly Lawrence W & Associates's Bioverativ Inc. Common Stock position peaked at $0 in Q1 2017.
  • 452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on Kelly Lawrence W & Associates's 13F filing for Q2 2017, filed 1 Aug 2017.